# A Dose Finding Study to Treat Bone Tumor(s)

> **NCT06008483** · PHASE1 · UNKNOWN · sponsor: **QSAM Therapeutics, Inc.** · enrollment: 17 (estimated)

## Conditions studied

- Bone Cancer
- Bone Tumor
- Solid Tumor
- Metastatic Cancer to the Bone
- Metastatic Tumor to the Bone

## Interventions

- **DRUG:** 153-Sm-DOTMP (Samarium-153-DOTMP)

## Key facts

- **NCT ID:** NCT06008483
- **Lead sponsor:** QSAM Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-05
- **Primary completion:** 2024-04-05
- **Final completion:** 2024-11-01
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06008483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06008483, "A Dose Finding Study to Treat Bone Tumor(s)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06008483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*